Condition: Hypothalamic Obesity · Prader-Willi Syndrome · PWS · Sponsor: Rhythm Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment
This description comes directly from the study's public registry record.
Rhythm Clinical Trials · (857) 264-4280 · clinicaltrials@rhythmtx.com
Physician Inquiry Clinical Trials · (857) 264-4280 · clinicaltrials@rhythmtx.com
Always discuss trial participation with your own doctor first.
| UAB Pediatric Endocrinology (Part C and Part D) | Birmingham, Alabama, United States | Recruiting |
| Ann and Robert H. Lurie Children's Hospital of Chicago (Part C and Part D) | Chicago, Illinois, United States | Recruiting |
| Boston Children's Hospital (Part C only) | Boston, Massachusetts, United States | Recruiting |
| Brigham and Women's Hospital (Part C and Part D) | Boston, Massachusetts, United States | Recruiting |
| Vanderbilt University Medical Center (Part C only) | Nashville, Tennessee, United States | Recruiting |
| Worldwide Clinical Trials (Part A and Part B) | San Antonio, Texas, United States | Completed |
| University of Utah Pediatric Endocrine Clinic (Part C and Part D) | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06239116